UNCY — Unicycive Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1766140 ·
Last close
$3.70
Market Cap
$101.35M
52W High
$8.74
52W Low
$3.33
ADV30
1,059,373
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -8,841,000 | -6,997,000 | 69,933,000 | 41,966,000 | 17,309,000 |
| Jun 2026 | 0 | — | -10,140,000 | -1,722,000 | 72,029,000 | 44,185,000 | 18,759,000 |
| Mar 2026 | 0 | — | -8,437,000 | -12,823,000 | 64,406,000 | 37,371,000 | 26,702,000 |
| Dec 2025 | 0 | — | -7,224,000 | -14,668,000 | 49,135,000 | 29,198,000 | 18,938,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-27,839,000
Investing CF
$-17,251,000
Financing CF
$66,948,000
CapEx
$-32,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-1.45
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-142,370,000
Inventory
—
Receivables
—
ST Investments
$17,240,000
EBIT TTM
$-35,182,000
Pretax Income TTM
$-35,224,000
Interest Exp TTM
$42,000
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -29,517,000 | -26,555,000 | 49,135,000 | 18,938,000 | 30,197,000 | -31,317,000 |
| Dec 2024 | 0 | -32,117,000 | -36,729,000 | 31,668,000 | 24,237,000 | 7,431,000 | -28,575,000 |
| Dec 2023 | 675,000 | -20,774,000 | -30,544,000 | 14,191,000 | 18,000,000 | -3,809,000 | -18,283,000 |
| Dec 2022 | 951,000 | -18,052,000 | -18,058,000 | 2,818,000 | 3,284,000 | -466,000 | -15,651,000 |
TTM Snapshot
Revenues TTM
$1,466,000
NetIncome TTM
$-35,223,000
OpCashFlow TTM
—
Assets (Latest)
$72,029,000
Forward EPS
$1.66
Max Pain — expiry 2028-01-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $3.57 · call volume: 205 · put volume: 2
Expected Move to 2028-01-21:
±$3.15
(88.24%) —
implied range
$0.42 –
$6.72
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OGI | ORGANIGRAM GLOBAL INC. | $101.90M | $0.71 | — |
| IMUX | IMMUNIC, INC. | $100.01M | $7.33 | — |
| EQ | Equillium, Inc. | $99.61M | $1.21 | — |
| NERV | Minerva Neurosciences, Inc. | $103.13M | $2.16 | — |
| ADAG | Adagene Inc. | $99.37M | $1.48 | — |
News headlines (Yahoo Finance, 1h cache)
Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
2026-11-17 09:09 · Yahoo
Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-04 23:06 · Yahoo
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission, PDUFA Date of March 25, 2027
2026-10-21 21:35 · Yahoo
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027
2026-10-21 11:05 · Yahoo
Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-10-13 12:35 · Yahoo
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
2026-10-01 11:05 · Yahoo
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
2026-09-29 11:05 · Yahoo
Unicycive Therapeutics shares rise after second-quarter loss beats forecasts
2026-08-12 12:00 · Yahoo
Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies
2026-07-01 22:13 · Yahoo
Unicycive shares plunge after FDA issues Complete Response Letter for kidney disease drug (UNCY)
2026-06-30 12:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.